- Polyrizon has initiated GMP manufacturing preparations for its PL-14 allergy blocker, aimed at a planned 2025 clinical trial.
- The company has partnered with Eurofins CDMO Amatsiaquitaine S.A.S. to ensure compliance with regulatory and quality standards.

Polyrizon, a biotech company focused on innovative intranasal hydrogels, has announced the commencement of Good Manufacturing Practice (GMP) manufacturing preparations for its PL-14 allergy blocker. This milestone is a critical step in readiness for the company’s planned 2025 clinical trial.
To support this effort, Polyrizon has partnered with Eurofins CDMO Amatsiaquitaine S.A.S., a GMP manufacturing organisation. The manufacturing facility is equipped to produce clinical trial materials (CTM) that meet stringent regulatory requirements and ensure high-quality production.
The clinical trial will evaluate the safety and efficacy of PL-14, an innovative nasal spray solution designed to address allergy-related health challenges. Polyrizon’s proprietary approach aims to provide novel intranasal solutions to meet growing global demand in the allergy treatment market.
“With the global nasal spray market projected to reach over $23 billion by 2029, driven by increasing demand for innovative and effective solutions, Polyrizon is proud to take this step forward in advancing our PL-14 allergy blocker toward clinical trial,” said Tomer Izraeli, CEO of Polyrizon. “By collaborating with Eurofins CDMO Amatsiaquitaine S.A.S., a leader in GMP manufacturing, we are committed to achieving the highest quality standards for our trial while addressing the market need with a novel intranasal solution that we believe has the potential to enhance current solutions.”